Valuation: Amarin Corporation plc

Market Cap 244M 218M 203M 184M 347M 23.15B 353M 2.44B 953M 12.08B 917M 898M 38.65B P/E 2026 *
-165x
P/E 2027 * -193x
Enterprise Value 82.11M 73.29M 68.12M 61.96M 117M 7.78B 119M 818M 320M 4.06B 308M 302M 12.98B EV / Sales 2026 *
0.46x
EV / Sales 2027 * 0.39x
Free-Float
86.93%
Yield 2026 *
-
Yield 2027 * -
1 day-0.34%
1 week-3.50%
Current month-11.00%
1 month-16.94%
3 months-19.99%
6 months-23.88%
Current year-17.09%
1 week 11.34
Extreme 11.34
11.93
1 month 11.34
Extreme 11.34
13.95
Current year 11.34
Extreme 11.34
17.31
1 year 11.34
Extreme 11.34
20.9
3 years 7.08
Extreme 7.08
27.4
5 years 7.08
Extreme 7.08
103.2
10 years 7.08
Extreme 7.08
522.4
Manager TitleAgeSince
Chief Executive Officer 63 2024-06-03
Director of Finance/CFO 42 2024-10-22
Compliance Officer 56 2023-11-14
Director TitleAgeSince
Director/Board Member 63 2024-06-03
Director/Board Member 43 2023-02-27
Director/Board Member 67 2023-02-27
Date Insider Type Main position Quantity % Market Cap. Importance
8/1/26 Exercice

Chief Financial Officer

781 0.0002%
7/1/26 Exercice

Chief Operating Officer

9,302 0.0022%
7/1/26 Exercice

Chief Technology Officer

9,263 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-3.50%-42.06%-23.81% 245M
+0.21%-4.63%+55.34%+71.32% 68.92B
+1.66%+7.51%+8.12%+60.04% 51.9B
+3.14%+7.17%+12.48%+44.42% 48.73B
+3.45%+4.70%+33.44%+35.96% 43.13B
-2.20%+0.61%+281.88%+532.76% 41.48B
+6.43%+6.84%+18.32%+109.23% 39.96B
+1.28%+1.39%+11.69%+45.10% 30.6B
-2.21%-10.09%+35.34%-0.94% 26.01B
+1.74%-2.02%-13.55%-12.92% 22.27B
Average +1.32%-1.20%+40.10%+86.12% 37.32B
Weighted average by Cap. +1.58%-0.25%+52.71%+105.22%

Financials

2026 *2027 *
Net sales 177M 158M 147M 134M 252M 16.81B 256M 1.77B 692M 8.77B 666M 652M 28.06B 177M 158M 147M 133M 251M 16.75B 256M 1.76B 689M 8.74B 664M 650M 27.96B
Net income -26.62M -23.76M -22.09M -20.09M -37.8M -2.52B -38.48M -265M -104M -1.32B -99.91M -97.79M -4.21B -18.32M -16.35M -15.2M -13.82M -26.01M -1.74B -26.48M -183M -71.43M -905M -68.75M -67.29M -2.9B
Net Debt -162M -145M -135M -122M -230M -15.37B -235M -1.62B -633M -8.02B -609M -596M -25.66B -175M -156M -145M -132M -248M -16.56B -253M -1.74B -682M -8.64B -656M -642M -27.65B
Projected Income Statement - Annual - Amarin Corporation plc
Logo Amarin Corporation plc
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Employees
80
Date Price Change Volume
26-10-15 US$11.57 -0.34% 54,355
26-10-14 US$11.61 +0.26% 51,010
26-10-13 US$11.58 +0.43% 102,387
26-10-12 US$11.53 -4.16% 90,041
26-10-09 US$12.03 +0.33% 44,854
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Amarin Corporation plc
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
11.57USD
Average target price
12.50USD
Spread / Average Target
+8.04%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amarin Corporation plc
  1. Stock Market
  2. Stocks
  3. AMRN Stock